CAPTRUST Financial Advisors
ATNM icon

CAPTRUST Financial Advisors’s Actinium Pharmaceuticals ATNM Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-166
Closed -$1K – 2213
2022
Q2 		$1K Sell
166
-1,000
-86% -$5.68K ﹤0.01% 4625
2022
Q1 		$6K Buy
1,166
+166
+17% +$874 ﹤0.01% 4048
2021
Q4 		$6K Buy
+1,000
New +$7.5K ﹤0.01% 3964

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

CAPTRUST Financial Advisors's ATNM Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Actinium Pharmaceuticals (ATNM) in Q3 2022, closing a stake of 166 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in ATNM in Q4 2021 and held it in 3 quarters. The position peaked at $6K in Q1 2022. 56 funds tracked by Wall St. Rank hold ATNM as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Actinium Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 166 Actinium Pharmaceuticals shares in Q3 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Actinium Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • CAPTRUST Financial Advisors's Actinium Pharmaceuticals position peaked at $6K in Q1 2022.
  • 56 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.